Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant - Wikidata - thesis-toulmin - TriplyDB

Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant

Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant

http://www.wikidata.org/entity/Q27638329

about

Current perspectives on HIV-1 antiretroviral drug resistance High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations.Structural Basis for the Inhibition of RNase H Activity of HIV-1 Reverse Transcriptase by RNase H Active Site-Directed Inhibitors Crystal Structure of tert -Butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in Complex with HIV-1 Reverse Transcriptase (RT) Redefines the Elastic Limits of the Non-nucleoside Inhibitor-Binding Pocket 8-Modified-2'-deoxyadenosine analogues induce delayed polymerization arrest during HIV-1 reverse transcription Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients Global Conformational Dynamics of HIV-1 Reverse Transcriptase Bound to Non-Nucleoside Inhibitors.Discovery of wild-type and Y181C mutant non-nucleoside HIV-1 reverse transcriptase inhibitors using virtual screening with multiple protein structures.Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding.Steered molecular dynamics simulation on the binding of NNRTI to HIV-1 RT.Mechanism of allosteric inhibition of HIV-1 reverse transcriptase revealed by single-molecule and ensemble fluorescence.Allosteric suppression of HIV-1 reverse transcriptase structural dynamics upon inhibitor binding Evaluation of anti-HIV-1 mutagenic nucleoside analogues.Differential isotopic enrichment to facilitate characterization of asymmetric multimeric proteins using hydrogen/deuterium exchange mass spectrometry.The HEPT Analogue WPR-6 Is Active against a Broad Spectrum of Nonnucleoside Reverse Transcriptase Drug-Resistant HIV-1 Strains of Different Serotypes.Structure of the HIV-1 reverse transcriptase Q151M mutant: insights into the inhibitor resistance of HIV-1 reverse transcriptase and the structure of the nucleotide-binding pocket of Hepatitis B virus polymerase.Acetylenic linkers in lead compounds: a study of the stability of the propargyl-linked antifolates.In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.Characterization of a subtype D human immunodeficiency virus type 1 isolate that was obtained from an untreated individual and that is highly resistant to nonnucleoside reverse transcriptase inhibitors.Mechanistic Study of Common Non-Nucleoside Reverse Transcriptase Inhibitor-Resistant Mutations with K103N and Y181C Substitutions Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase.Double Variational Binding--(SMILES) Conformational Analysis by Docking Mechanisms for Anti-HIV Pyrimidine Ligands.Efavirenz binding site in HIV-1 reverse transcriptase monomers.The interplay of structure and dynamics: insights from a survey of HIV-1 reverse transcriptase crystal structures.HIV reverse transcriptase: structural interpretation of drug resistant genetic variants from India.Efavirenz binding to HIV-1 reverse transcriptase monomers and dimers.HIV-1 viral load determination based on reverse transcriptase activity recovered from human plasma.Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine.Evaluation of etravirine resistance in clinical samples by a simple phenotypic test.Multiple drugs and multiple targets: an analysis of the electrostatic determinants of binding between non-nucleoside HIV-1 reverse transcriptase inhibitors and variants of HIV-1 RT.Revealing the drug-resistant mechanism for diarylpyrimidine analogue inhibitors of HIV-1 reverse transcriptase.Drug resistant mechanism of diaryltriazine analog inhibitors of HIV-1 reverse transcriptase using molecular dynamics simulation and 3D-QSAR.Current state-of-the-art in preclinical and clinical development of novel non-nucleoside HIV-1 reverse transcriptase inhibitors

P2860

Q26852626-F7A9214D-186F-44D0-AB5E-E361F0643109 Q27649731-11280CB7-264D-4777-A79B-FB4EBF6F8ADC Q27661750-4258FC1A-E8C3-4409-89F4-708B667507D6 Q27667348-61528E4C-89A2-4CD5-81C1-856BCC727316 Q28477840-B5F9DEFF-521F-4985-85CB-4F077FA803E6 Q33558937-2535BA3C-1E49-40CF-A2B3-91AC67ED410A Q33565179-DD63887C-64FA-415A-88ED-54A22570C14F Q33635679-6CF8C11F-9E9A-4601-98B5-D7BB58A7F9F4 Q33768822-6BEBDB88-AE47-4F95-B011-038EE32D81CA Q34163065-301D7C48-2B03-40F0-9572-E30187257945 Q34181367-F411A58B-E8A5-48DD-A8DD-795EB129F92D Q34313002-66F40605-2848-4F47-A3E6-1E32EC17DE90 Q34439424-C1F58FF8-3960-429D-9A37-51C1EF07A79A Q34801497-EE4BD2B5-3DB1-4F73-96C3-10BD52EC46A1 Q35654238-BF08C0CE-0351-4B02-B87F-81C543E12149 Q35859896-BAF1C545-61F7-4313-BD5B-E6F0DA0B814A Q36244591-4AB7397A-DDB3-4CEA-A40B-05332EEA7DB7 Q36296178-CB057527-148F-4278-BAB9-155B18A1FC02 Q37643598-B536B326-3F5B-49C7-B789-9CE6484BA6D1 Q37730522-5E88A273-289E-43F2-9C25-08A4652DD988 Q39350740-4F5470D8-AEE3-411B-9A65-A927B7970FF6 Q39912641-7DAF0E29-051C-498B-8797-F3F69BDA3D4A Q41040182-B75A3EF4-A13B-44F2-92BD-0D3825A02895 Q41480004-847AD2FA-B3B2-47E1-BCC5-34F6A3A75E0D Q41761359-2B7CA3CF-6773-47AF-A6BB-BCD158BA3983 Q42601729-67FA2251-00BB-413D-A79F-EA703ED50BCD Q42738742-FD66F421-6A97-4807-8A52-11CB15C69BAD Q44579682-7CDF3DCF-6107-40B6-877B-7153BE5A7FAD Q46230871-F7F05D23-390F-4E06-A5FC-1E0E2648EE76 Q50107451-377F1142-08C9-4D5B-BCAD-F0F6FA32EBD3 Q54549089-6B006FCE-9CD9-4516-A7D4-AC9E4CC78128 Q54579751-A16F7ED2-0A2B-4137-979A-B020E9FA0944 Q54628424-A2E295CB-CF52-4844-B971-26EEFA35C065 Q57266180-224C489C-C710-45BC-B670-BB0D0C8B3031

P2860

Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant

http://www.wikidata.org/entity/Q27638329

description

2002 nî lūn-bûn

@nan

2002 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի մարտին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Structural basis for the inhib ...... ards the HIV-1 RT K103N mutant

@ast

Structural basis for the inhib ...... ards the HIV-1 RT K103N mutant

@en

Structural basis for the inhib ...... ards the HIV-1 RT K103N mutant

@nl

type

label

Structural basis for the inhib ...... ards the HIV-1 RT K103N mutant

@ast

Structural basis for the inhib ...... ards the HIV-1 RT K103N mutant

@en

Structural basis for the inhib ...... ards the HIV-1 RT K103N mutant

@nl

prefLabel

Structural basis for the inhib ...... ards the HIV-1 RT K103N mutant

@ast

Structural basis for the inhib ...... ards the HIV-1 RT K103N mutant

@en

Structural basis for the inhib ...... ards the HIV-1 RT K103N mutant

@nl

P1433

Q27638329-38FD019F-970F-4D95-A26C-DDEB386194DD

P1476

Q27638329-29CA8AB6-ECB7-45DA-9381-4C73362D137C

P2093

Q27638329-1CEDC5AC-0172-4AFA-834A-F39D42AAF8DE

Q27638329-1E336DA4-E52F-46D7-B634-4F33881574C0

Q27638329-32D334C7-7EC1-4C13-BFCB-C970376A5BA0

Q27638329-401D6712-8B7F-48C1-BD3C-B39ACACFD9C1

Q27638329-8B5822BC-D48A-4FA5-B22C-B9D2BEC96AAF

Q27638329-BBD2DB03-4BDB-4007-954D-470FCD5DC069

Q27638329-C8B73E77-EC78-4298-9A26-52D4C2C9E6E6

Q27638329-D54165AF-0BFD-497C-85E2-342DDD7994A0

P2860

Q27638329-0C031F4D-EC65-451B-BFA2-C36688BD86FF

Q27638329-14A20BB4-0652-4D87-9FA0-021228A6A9D8

Q27638329-1A059526-B200-4C15-898F-D4EDBA2FECBD

Q27638329-309D971A-D280-453D-B2D5-709854CD58AB

Q27638329-327E7545-EBEB-4E9C-A509-3F8F4CE236CE

Q27638329-4675B2E7-C9B9-4578-80B0-EBFC46B5EC5F

Q27638329-66D6ACC7-A701-4066-BBB0-28841B4B3B96

Q27638329-6C9AF0DE-C6C2-4727-BCB8-8F646B1F4E93

Q27638329-7FAB0936-1F2E-46C5-A213-353ADDAD7179

Q27638329-858B3D4A-2CFE-46AE-821C-1DCA17280182

P304

Q27638329-54346894-B0ED-4305-8254-201852870F89

P31

Q27638329-EC4ACD54-9122-4C26-BA29-BCB8E350865E

P3181

Q27638329-1C5AB549-82E2-4FC3-959C-777D7CDE221B

P356

Q27638329-687916C5-FCB4-4267-81FA-50E2A4E83ED9

P407

Q27638329-F5999CFF-74F1-4EAE-87E9-4011BACBCC65

P433

Q27638329-CA822755-7606-46A6-948B-26E4936D249A

P478

Q27638329-47E31CA3-23C2-4FC4-AD19-72E7E2ABFD33

P50

Q27638329-E4DBCE88-3A8D-4C04-944B-728EC08EA856

P577

Q27638329-3751BE59-C932-4415-9304-B914282D5110

P5875

Q27638329-6FDA4A7E-DF52-4846-9676-DED0F1E7B023

P698

Q27638329-DA10EE95-FD77-4D2F-9726-DD00BF610707

P3181

P356

J.1432-1327.2002.02811.X

P1433

P1476

Structural basis for the inhib ...... ards the HIV-1 RT K103N mutant

@en

P2093

Christer Sahlberg

http://www.w3.org/2001/XMLSchema#string

Hans O Andersson

http://www.w3.org/2001/XMLSchema#string

Hong Zhang

http://www.w3.org/2001/XMLSchema#string

Jimmy Lindberg

http://www.w3.org/2001/XMLSchema#string

Kerstin Fridborg

http://www.w3.org/2001/XMLSchema#string

Rolf Noréen

http://www.w3.org/2001/XMLSchema#string

Seved Löwgren

http://www.w3.org/2001/XMLSchema#string

Torsten Unge

http://www.w3.org/2001/XMLSchema#string

P2860

Improved methods for building protein models in electron density maps and the location of errors in these models

Processing of X-ray diffraction data collected in oscillation mode

Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues

Binding of the second generation non-nucleoside inhibitor S-1153 to HIV-1 reverse transcriptase involves extensive main chain hydrogen bonding

Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase

The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance

Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors

Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors

Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: implications of conformational changes for polymerization and inhibition mechanisms

Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant

P304

1670-1677

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3363729

http://www.w3.org/2001/XMLSchema#string

P356

10.1046/J.1432-1327.2002.02811.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

269

http://www.w3.org/2001/XMLSchema#string

P50

Snaevar Sigurdsson

P577

2002-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11468942

http://www.w3.org/2001/XMLSchema#string

P698

11895437

http://www.w3.org/2001/XMLSchema#string